Antibody imaging in the evaluation of cardiovascular diseases.
Antimyosin antibody was originally developed for in vivo detection of acute myocardial infarction. However, its utility has expanded to include diagnosis of various cardiovascular diseases in which myocyte necrosis constitutes an obligatory component of the disease. Thus antimyosin has also been used clinically for noninvasive diagnosis of acute myocarditis, heart transplant rejection, drug-induced cardiotoxicity, and other cardiomyopathies. This first-generation monoclonal antibody, antimyosin, has opened the way for the second-generation monoclonal antibodies such as antifibrin and antiplatelet for in vivo diagnostic use in the detection of deep venous thrombosis and pulmonary embolism and antiatherosclerotic lesion-specific antibody for diagnosis of metabolically active lesions. Whether the third generation of antibodies will include ultrasmall antigen-binding units or negative charge-modified antibodies must await future studies.
Khaw
B A
BA
Bouvé College of Pharmacy and Health Sciences, Northeastern University, Boston, MA 02115, USA.
Narula
J
J
D000818:Animals; D001161:Arteriosclerosis; D002318:Cardiovascular Diseases / Q000000981:diagnostic imaging*; D005337:Fibrin / Q000276:immunology; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D009203:Myocardial Infarction / Q000000981:diagnostic imaging; D009205:Myocarditis / Q000000981:diagnostic imaging; D009218:Myosins / Q000276:immunology; D016719:Radioimmunodetection
D005337:Fibrin; D009218:Myosins